Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs
Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs
复制标题
DOI：
10.2217/bmm.09.48
复制
发表时间：
2009-12-01
影响因子：
2.2
通讯作者：
Heinzelmann-Schwarz, Viola
中科院分区：
文献类型：
--
作者：
Jacob, Francis;Goldstein, Darlene R.;Heinzelmann-Schwarz, Viola
在过去的十年里，人们一直在努力提高我们对卵巢癌复杂生物学的理解。发表的蛋白质基因组学研究的线性增长已经解决了关于其分子发病机制的各种问题。许多基因已被转录组学方法鉴定，其中一些被研究作为推定的肿瘤标志物（HE4， OPN， Ep-CAM和Mesothelin），而其他基因则是分子治疗方法的潜在靶点（VEGF, 104， EGFR, MUC1， CLDN4和SLPI）。蛋白质基因组学有可能进一步改变我们目前对卵巢癌的表征和治疗。其他进展将取决于综合研究设计、跨学科合作、使用强大的高通量平台以及统一的生物信息学分析指南。
There has been a concerted effort over the last decade to improve our understanding of the complex biology of ovarian cancer. A linear growth in published proteogenomic studies has addressed a variety of questions regarding its molecular pathogenesis. A number of genes have been identified by transcriptomic approaches, some of which are being investigated as putative tumor markers (HE4, OPN, Ep-CAM and Mesothelin), whilst others are potential targets for molecular therapeutic approaches (VEGF, 104, EGFR, MUC1, CLDN4 and SLPI). Proteogenomics has the potential to further change our current characterization and treatment of ovarian cancer. Additional advances will depend on integrated study designs, interdisciplinary collaborations, use of robust high-throughput platforms, as well as uniform guidelines for bioinformatic analyses.